⚡️⚡️⚡️
With energy prices rising, switch to a cheaper plan
💡
Compare Prices Now
⚡️⚡️⚡️

How to buy CSL (CSL) shares

Learn how to easily invest in CSL shares.

We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!

CSL (CSL) is an Australian biotechnology company that specialises in blood plasmas, vaccines and anti-venoms. The world's largest collector of blood plasmas, CSL is also one of Australia's 5 biggest companies by market capitalisation. In 2020, it agreed to manufacture the AstraZeneca COVID-19 vaccine for the Australian government.

How to buy shares in CSL

  1. Compare share trading platforms. To buy shares listed in Australia, you'll need to sign up to a broker with access to the ASX. Our table can help you choose.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, such as your ID and tax file number. Fund your account with a bank transfer, PayPal or debit card.
  3. Search for CSL. Find the share by name or ticker symbol: CSL. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until CSL reaches your desired price. Look into dollar-cost averaging to spread out your risk, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At today's price, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs.
  6. Check on your investment. Congratulations, you own a part of CSL. Optimise your portfolio by tracking how your stock and the business performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that affect your stock.

CSL stock price (ASX:CSL)

Use our graph to track the performance of CSL stocks over time.

CSL shares at a glance

Information last updated 2022-06-27.
52-week range$238.7774 - $318.0184
50-day moving average $269.7276
200-day moving average $279.5306
Target price$318.64
PE ratio 37.4126
Dividend yield $2.22 (1.09%)
Earnings per share (TTM) $7.297

Compare share trading platforms

The value of your investments can fall as well as rise and you may get back less than you invested. Past performance is no indication of future results.
1 - 9 of 9
Name Product Standard brokerage fee Inactivity fee Markets
ThinkMarkets Share Trading
$8
No
ASX shares
Exclusive: Sign up through Finder and get 3 months of free trading up to 50 trades. Offer available to new customers only.
Following your first three months, enjoy $8 flat fee CHESS sponsored brokerage as well as free live stock data all from the convenience of an easy-to-use mobile app
IG Share Trading
$5 – 8
No
ASX shares, US shares, UK shares, ETFs, and more
Exclusive: Finder customers who apply for a share trading account in June will be able to trade Aussie shares from $2.50 commission until the end of August. T&Cs apply.
Enjoy some of the lowest brokerage fees on the market when trading Australian shares, international shares, plus get access to 24-hour customer support.
Tiger Brokers
Exclusive
Tiger Brokers
$6.49
No
ASX shares, Global shares, Options trading, US shares, ETFs
Exclusive to Finder: Sign up to Tiger through Finder and on completion of your first deposit of any amount or transfer of shares receive 4 extra free grab shares. T&Cs apply.
Get started with $0 brokerage on ASX and US stocks for the first 3 months upon completion of your first qualifying deposit. Also receive a free Apple share if you deposit $3,000 or more.
SelfWealth (Basic account)
$9.5
No
ASX shares, US shares
Trade ASX and US shares for a flat fee of $9.50, regardless of the trade size.
New customers receive free access to Community Insights with SelfWealth Premium for the first 90 days. Follow other investors and benchmark your portfolio performance.
Bendigo Invest Direct
$19.95
No
ASX shares, Global shares, Options trading, mFunds, ETFs, Warrants
Gain access to 12 markets from one account with Bendigo.
Invest in Australian shares and access major international markets through a trusted local brand. Plus, fine tune your investment knowledge with Bendigo’s advanced research and analysis tools.
GO Markets Share Trading
$7.70
No
ASX shares, Forex, CFDs, ETFs
Zero Brokerage on your next 50 trades!
Simply transfer an existing HIN before 30 June and pay no fees on your next 50 transactions. Alternatively, transfer your existing shares and receive 5 transactions at zero cost for each shareholding transferred, once again up to 50 free trades. T & Cs apply
Saxo Capital Markets (Classic account)
$5
No
ASX shares, Global shares, ETFs
Access 22,000+ stocks on 50+ exchanges worldwide
Low fees for Australian and global share trading, no inactivity fees, low currency conversion fee and optimised for mobile.
Bell Direct Share Trading
$15
No
ASX shares, mFunds, ETFs
Get $300 free brokerage until 30 June when you move to Bell Direct. T&Cs apply.
Bell Direct offers a one-second placement guarantee on market-to-limit ASX orders or your trade is free, plus enjoy extensive free research reports from top financial experts.
Superhero share trading
$5
No
ASX shares, US shares, ETFs
Sign up & fund your account with A$100 or more and receive US$10 of Tesla stocks on Superhero. T&Cs apply.
Enjoy $0 brokerage on US stocks and buying ETFs as well as a flat $5 fee to trade Australian shares.
loading

Compare up to 4 providers

Is it a good time to buy CSL stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

CSL price performance over time

Historical closes compared with the last close of A$273

1 week (2022-06-20) 3.79%
1 month (2022-05-27) 1.48%
3 months (2022-03-28) 4.25%
6 months (2021-12-24) -6.78%
1 year (2021-06-28) -5.35%
2 years (2020-06-26) -6.74%
3 years (2019-06-28) 26.98%
5 years (2017-06-27) 93.89%

Is CSL under- or over-valued?

Valuing CSL stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of CSL's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

CSL's P/E ratio

CSL's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 37x. In other words, CSL shares trade at around 37x recent earnings.

That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

CSL's EBITDA

CSL's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $3.4 billion (£1.9 billion).

The EBITDA is a measure of a CSL's overall financial performance and is widely used to measure a its profitability.

CSL financials

Revenue TTM $10.6 billion
Operating margin TTM 28.31%
Gross profit TTM $5.8 billion
Return on assets TTM 9.13%
Return on equity TTM 20.96%
Profit margin 21.91%
Book value 29.312
Market capitalisation $131.5 billion

TTM: trailing 12 months

CSL's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like CSL.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

CSL's total ESG risk score

Total ESG risk: 27.73

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and CSL's overall score of 27.73 (as at 01/01/2019) is pretty good – landing it in it in the 40th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like CSL is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

CSL's environmental score

Environmental score: 3.04/100

CSL's environmental score of 3.04 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

CSL's social score

Social score: 18.57/100

CSL's social score of 18.57 puts it squarely in the 5th percentile of companies rated in the same sector. This could suggest that CSL is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

CSL's governance score

Governance score: 11.12/100

CSL's governance score puts it squarely in the 5th percentile of companies rated in the same sector. That could suggest that CSL is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

CSL's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. CSL scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that CSL has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

CSL Ltd was last rated for ESG on: 2019-01-01.

Total ESG score 27.73
Total ESG percentile 39.7
Environmental score 3.04
Environmental score percentile 5
Social score 18.57
Social score percentile 5
Governance score 11.12
Governance score percentile 5
Level of controversy 2

CSL share dividends

43%

Dividend payout ratio: 43.25% of net profits

Recently CSL has paid out, on average, around 43.25% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 1.09% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), CSL shareholders could enjoy a 1.09% return on their shares, in the form of dividend payments. In CSL's case, that would currently equate to about A$2.22 per share.

While CSL's payout ratio might seem fairly standard, it's worth remembering that CSL may be investing much of the rest of its net profits in future growth.

The latest dividend was paid out to all shareholders who bought their shares by 7 March 2022 (the "ex-dividend date").

Have CSL's shares ever split?

CSL's shares were split on a 3:1 basis on 18 October 2007. So if you had owned 1 share the day before the split, the next day you would own 3 shares. This wouldn't directly have changed the overall worth of your CSL shares – just the quantity. However, indirectly, the new 66.7% lower share price could have impacted the market appetite for CSL shares which in turn could have impacted CSL's share price.

CSL share price volatility

Over the last 12 months, CSL's shares have ranged in value from as little as $238.7774 up to $318.0184. A popular way to gauge a stock's volatility is its "beta".

Beta measures a share's volatility in relation to the market. The market (AU average) beta is 1, while CSL's is 0.1043. This would suggest that CSL's shares are less volatile than average (for this exchange).

CSL overview

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. The company operates through two segments, CSL Behring and Seqirus. The CSL Behring segment offers plasma therapies, such as plasma products and recombinants for the treatment of immunodeficiency, bleeding disorders, hereditary angioedema, Alpha-1 antitrypsin deficiency, and neurological disorders. This segment also conducts research on plasma and non-plasma therapies; and receives license and royalty from the commercialization of intellectual property. The Seqirus segment manufactures and distributes non-plasma biotherapeutic products; and develops influenza related products. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs comes with a higher risk of losing money rapidly due to leverage. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com.au:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com.au is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder only provides general advice and factual information, so consider your own circumstances, or seek advice before you decide to act on our content. By submitting a question, you're accepting our Terms of Use, Disclaimer & Privacy Policy and Privacy & Cookies Policy.
Go to site